Anhydrovinblastine

Drug Profile

Anhydrovinblastine

Alternative Names: Anhydrovinblastine - IGT Pharma; KRX 0403

Latest Information Update: 03 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of British Columbia
  • Class Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 03 Sep 2007 Discontinued - Phase-II for Solid tumours in USA (unspecified route)
  • 12 Jul 2005 Phase-II clinical trials in Solid tumours in USA (unspecified route)
  • 12 Feb 2004 ACCESS Oncology has been acquired by Keryx Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top